PCN213 COST-UTILITY ANALYSIS OF ABIRATERONE IN THE TREATMENT OF DOCETAXEL-REFRACTORY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COMPARED TO BEST SUPPORTIVE CARE IN IRAN.

So far, there is no anti-tumor therapy available in Iran for patients with metastatic castration resistant prostate cancer (mCRPC) who progressed after receiving chemotherapy with docetaxel. This research aims to evaluate the cost-utility of Abiraterone in the treatment of docetaxel-refractory mCRPC patients compared to best supportive care (BSC), including prednisolone and palliative care, from the Iranian payer perspective. [Extracted from the article]